Literature DB >> 1868387

Tumour dormancy: initiation, maintenance and termination in animals and humans.

T H Stewart1, A C Hollinshead, S Raman.   

Abstract

The authors review the natural occurrence of tumour dormancy in man and animal models, which show the importance of cellular defence mechanisms in inducing and maintaining the state of tumour dormancy. Six cases of non-small-cell lung cancer are described. The patients exhibited moderate to very strong delayed hypersensitivity reactions to soluble lung-cancer antigen after specific immunotherapy. Three patients had nonregional metastases at 11, 12 and 14 years. Two had regional recurrence after 9 years, and in one patient a small hilar-node metastasis was found at autopsy after 7.6 years. In each case an immunodepressive event or drug treatment preceded resurgent growth. The effect of renal transplantation in patients with a history of surgery for cancer supports the conclusion that cellular defence mechanisms are crucial for the maintenance of tumour dormancy in man.

Entities:  

Mesh:

Year:  1991        PMID: 1868387

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  6 in total

1.  Breast Cancer: A Revolutionary Concept.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

Review 2.  Angiogenesis, metastasis, and endogenous inhibition.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 3.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 4.  Eicosanoids and the immunology of cancer.

Authors:  M R Young
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

Review 5.  Immunotherapy of cancer: targeting cancer during active disease or during dormancy?

Authors:  Syed Ammer Shah; Melika Zarei; Saeed H Manjili; Georgi Guruli; Xiang-Yang Wang; Masoud H Manjili
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

Review 6.  An alternative approach for treatment of breast cancer.

Authors:  D E Swartzendruber; M W Retsky; R H Wardwell; P D Bame
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.